FI4182308T3 - Pyridatsinyyliaminojohdannaisia alk5-estäjinä - Google Patents
Pyridatsinyyliaminojohdannaisia alk5-estäjinä Download PDFInfo
- Publication number
- FI4182308T3 FI4182308T3 FIEP21743186.5T FI21743186T FI4182308T3 FI 4182308 T3 FI4182308 T3 FI 4182308T3 FI 21743186 T FI21743186 T FI 21743186T FI 4182308 T3 FI4182308 T3 FI 4182308T3
- Authority
- FI
- Finland
- Prior art keywords
- yyli
- kloori
- fluorifenyyli
- pyridatsin
- metyylipyridatsin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20185890 | 2020-07-15 | ||
| PCT/EP2021/069649 WO2022013307A1 (en) | 2020-07-15 | 2021-07-14 | Pyridazinyl amino derivatives as alk5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4182308T3 true FI4182308T3 (fi) | 2024-12-07 |
Family
ID=71620257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21743186.5T FI4182308T3 (fi) | 2020-07-15 | 2021-07-14 | Pyridatsinyyliaminojohdannaisia alk5-estäjinä |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12479826B2 (https=) |
| EP (1) | EP4182308B1 (https=) |
| JP (1) | JP7686741B2 (https=) |
| KR (1) | KR20230051500A (https=) |
| CN (1) | CN116096719B (https=) |
| AR (1) | AR122986A1 (https=) |
| AU (1) | AU2021307559A1 (https=) |
| BR (1) | BR112023000588A8 (https=) |
| CA (1) | CA3184990A1 (https=) |
| DK (1) | DK4182308T3 (https=) |
| ES (1) | ES2997111T3 (https=) |
| FI (1) | FI4182308T3 (https=) |
| HR (1) | HRP20241617T1 (https=) |
| HU (1) | HUE069150T2 (https=) |
| MX (1) | MX2023000521A (https=) |
| PL (1) | PL4182308T3 (https=) |
| PT (1) | PT4182308T (https=) |
| SI (1) | SI4182308T1 (https=) |
| WO (1) | WO2022013307A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7702205B2 (ja) * | 2021-09-15 | 2025-07-03 | 株式会社東芝 | 新規アミン化合物、酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去 |
| CN114957331A (zh) * | 2022-04-22 | 2022-08-30 | 北京康辰药业股份有限公司 | 磷酸酯取代的环丙酰胺衍生喹唑啉类化合物的制备方法 |
| WO2024180206A1 (en) | 2023-03-02 | 2024-09-06 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| WO2024180207A1 (en) | 2023-03-02 | 2024-09-06 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| KR20240159754A (ko) * | 2023-04-28 | 2024-11-06 | 한국원자력의학원 | N-메틸피페라진 에탄올 카바메이트(N-methylpiperazine ethanol carbamate) 구조를 포함하는 신규 화합물 및 이의 용도 |
| WO2025132458A1 (en) | 2023-12-18 | 2025-06-26 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| WO2025132460A1 (en) | 2023-12-18 | 2025-06-26 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60001229T2 (de) | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CA2423050A1 (en) | 2000-09-20 | 2002-03-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| JP2006503043A (ja) * | 2002-09-10 | 2006-01-26 | サイオス インク． | ＴＧＦβ阻害剤 |
| AU2004278382B2 (en) * | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| BRPI0714409A2 (pt) | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
| ES2375425T3 (es) | 2007-07-26 | 2012-02-29 | Novartis Ag | Compuestos org�?nicos. |
| BRPI0817434A2 (pt) | 2007-10-17 | 2015-06-16 | Novartis Ag | Composto orgânicos |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| MX2010007604A (es) | 2008-01-11 | 2010-08-02 | Novartis Ag | Pirimidinas como inhibidores de cinasa. |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| EA201001687A1 (ru) | 2008-04-29 | 2011-06-30 | Новартис Аг | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) |
| CN102596200A (zh) * | 2009-11-07 | 2012-07-18 | 默克专利有限公司 | 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类 |
| DK2731949T3 (en) | 2011-07-13 | 2018-06-14 | Tiumbio Co Ltd | 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS |
| HRP20201384T1 (hr) * | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| US20200247812A1 (en) * | 2018-07-10 | 2020-08-06 | Integral Biosciences Private Limited | Heterocyclic compounds and methods of use |
-
2021
- 2021-07-14 PT PT217431865T patent/PT4182308T/pt unknown
- 2021-07-14 CN CN202180061803.6A patent/CN116096719B/zh active Active
- 2021-07-14 FI FIEP21743186.5T patent/FI4182308T3/fi active
- 2021-07-14 WO PCT/EP2021/069649 patent/WO2022013307A1/en not_active Ceased
- 2021-07-14 MX MX2023000521A patent/MX2023000521A/es unknown
- 2021-07-14 PL PL21743186.5T patent/PL4182308T3/pl unknown
- 2021-07-14 ES ES21743186T patent/ES2997111T3/es active Active
- 2021-07-14 US US18/014,764 patent/US12479826B2/en active Active
- 2021-07-14 AU AU2021307559A patent/AU2021307559A1/en active Pending
- 2021-07-14 HU HUE21743186A patent/HUE069150T2/hu unknown
- 2021-07-14 SI SI202130217T patent/SI4182308T1/sl unknown
- 2021-07-14 CA CA3184990A patent/CA3184990A1/en active Pending
- 2021-07-14 EP EP21743186.5A patent/EP4182308B1/en active Active
- 2021-07-14 BR BR112023000588A patent/BR112023000588A8/pt unknown
- 2021-07-14 HR HRP20241617TT patent/HRP20241617T1/hr unknown
- 2021-07-14 DK DK21743186.5T patent/DK4182308T3/da active
- 2021-07-14 KR KR1020237005127A patent/KR20230051500A/ko not_active Withdrawn
- 2021-07-14 JP JP2023502861A patent/JP7686741B2/ja active Active
- 2021-07-15 AR ARP210101996A patent/AR122986A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK4182308T3 (da) | 2024-10-21 |
| BR112023000588A2 (pt) | 2023-01-31 |
| ES2997111T3 (en) | 2025-03-19 |
| AR122986A1 (es) | 2022-10-19 |
| TW202216677A (zh) | 2022-05-01 |
| HRP20241617T1 (hr) | 2025-01-31 |
| CA3184990A1 (en) | 2022-01-20 |
| WO2022013307A1 (en) | 2022-01-20 |
| PT4182308T (pt) | 2024-12-04 |
| AU2021307559A1 (en) | 2023-02-16 |
| JP2023533849A (ja) | 2023-08-04 |
| KR20230051500A (ko) | 2023-04-18 |
| US12479826B2 (en) | 2025-11-25 |
| BR112023000588A8 (pt) | 2023-05-09 |
| JP7686741B2 (ja) | 2025-06-02 |
| EP4182308A1 (en) | 2023-05-24 |
| US20240018122A1 (en) | 2024-01-18 |
| CN116096719A (zh) | 2023-05-09 |
| SI4182308T1 (sl) | 2025-04-30 |
| HUE069150T2 (hu) | 2025-02-28 |
| PL4182308T3 (pl) | 2025-01-07 |
| EP4182308B1 (en) | 2024-09-04 |
| CN116096719B (zh) | 2025-09-30 |
| MX2023000521A (es) | 2023-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4182308T3 (fi) | Pyridatsinyyliaminojohdannaisia alk5-estäjinä | |
| SI3009428T1 (en) | DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS | |
| CY1110798T1 (el) | Συνδυασμοι περιλαμβανοντες αντιμουσκαρινικους παραγοντες και αναστολεις pde4 | |
| PE20120252A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| AR102852A1 (es) | Inhibidores heterocíclicos de la calicreína plasmática | |
| NO20082476L (no) | Bicykliske forbindelser med kinaseinhiberende aktivitet | |
| SI2834239T1 (en) | Heterobicyclic compounds as inhibitors of beta-lactamase | |
| CA2419552A1 (en) | Substituted pyrazoles | |
| HRP20201337T1 (hr) | Inhibitori lizin-specifične demetilaze-1 | |
| CA2499134A1 (en) | Fused azole-pyrimidine derivatives | |
| BRPI0507065B8 (pt) | derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| IL282006A (en) | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
| WO2007103970A3 (en) | Compositions and methods for treating respiratory disorders | |
| DK4053128T3 (da) | 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidinderivater og relaterede forbindelser som trk-kinasehæmmere til cancerbehandling | |
| HRP20251641T1 (hr) | Oblici čvrstog stanja (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida i njihova uporaba | |
| CA2685724A1 (en) | New use 541 | |
| MA44935A1 (fr) | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires | |
| JP2019520412A5 (https=) | ||
| MXPA03010054A (es) | Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos. | |
| WO2006065755A3 (en) | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists | |
| TW200722091A (en) | Combinations, methods and compositions for treating cancer | |
| EP3638241A4 (en) | PHARMACEUTICAL FORMULATIONS OF N- (2- (2- (DIMETHYLAMINO) ETHOXY) -4-METHOXY-5 - ((4- (1-METHYL-1H-INDOLE-3-YL) PYRIMIDINE-2-YL) AMINO) PHENYL) ACRYLAMIDE AND SALTS OF THIS LATEST | |
| HRP20200958T1 (hr) | Sredstva i postupci za liječenje i sprečavanje seboroične keratoze |